Insmed brensocatib fails Phase 2b CRSsNP; acquires INS1148 antibody

INSMED Inc

Phase 2b BiRCh study missed primary endpoint: placebo LS mean -2.44, brensocatib 10mg -2.21, 40mg -2.33.
All secondary endpoints also not met; Insmed discontinues CRSsNP program immediately.
Brensocatib well tolerated with no new safety signals; 40 mg dose had 69.9% TEAEs vs 65.3% placebo.
Acquired INS1148 (anti-SCF248 mAb) from Opsidio; plans Phase 2 in interstitial lung disease and asthma.
INS1148 targets only inflammatory c-Kit signaling, sparing homeostatic pathways, potentially first-in-class.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.